Vanda Pharmaceuticals Inc. VNDA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
0.13
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $216.1M | -$220.5M | — | -$110.4M | $327.2M |
| 2024 | $198.8M | -$18.9M | — | -$16.2M | $538.5M |
| 2023 | $192.6M | $2.5M | — | $12.4M | $544.9M |
| 2022 | $254.4M | $6.3M | — | $31.3M | $527.2M |
| 2021 | $268.7M | $33.2M | — | $63.7M | $504.9M |
| 2020 | $248.2M | $23.3M | — | $50.0M | $453.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| McGuire Daniel Patrick | SVP, GC and Secretary | 2026-06-04 | Grant | 80,000 | — |
| Chrousos Phaedra | director | 2026-06-04 | Grant | 41,600 | — |
| Duncan Charles Cliff | director | 2026-06-04 | Grant | 41,600 | — |
| DUGAN RICHARD W | director | 2026-06-04 | Grant | 41,600 | — |
| Ward Anne Sempowski | director | 2026-06-04 | Grant | 41,600 | — |
| Honore Tage | director | 2026-06-04 | Grant | 41,600 | — |
| Mitchell Stephen Ray | director | 2026-06-04 | Grant | 41,600 | — |
| Mitchell Stephen Ray | director | 2026-05-18 | Gift | 25,836 | — |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.13 (distress)
- Working capital / assets 0.413
- Retained earnings / assets -0.807
- EBIT / assets -0.309
- Equity / liabilities 2.023
Source: SEC EDGAR filings · CIK 0001347178 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.